Where this was said
The OSK Gene Therapy and First Human Trial
At 11:11 · chapter starts 5:13
In a remarkable moment of science communication, Sinclair produces a spiked rubber ball from his pocket to illustrate the virus-like particle his lab has engineered to deliver youth-restoring genes into human eyes. The capsule, he explains, carries three genes called OSK — a modified version of Shinya Yamanaka's Nobel Prize-winning reprogramming cocktail — along with surface proteins that target it to specific tissues. The first human patient, nearly totally blind from glaucoma, received trillions of these capsules injected into his eye earlier this year, bravely volunteering to be first. Nothing has gone wrong. Sinclair explains the scientific rationale: every cell in the human body still carries an intact backup copy of its youthful programming. OSK reads and reinstalls that backup, returning 92-year-old cells to a 25-year-old state while preserving their identity — a crucial difference from the full Yamanaka reset that creates dangerous stem cells.
Sinclair's lab is running the first FDA-approved human trial to reverse aging using virus-like capsules carrying OSK genes. The first patient — nearly totally blind — received trillions of these capsules injected into his eye, and so far nothing has gone wrong.
Sinclair's lab is conducting the first FDA-approved human clinical trial using OSK gene-therapy capsules injected into the eyes of glaucoma patients.
Every cell in your body still carries an intact backup copy of the instructions that made you young. OSK gene therapy reads that backup and reinstalls it — turning 92-year-old cells back to their 25-year-old state without erasing their identity or causing cancer.
Shinya Yamanaka won the Nobel Prize for turning adult cells into stem cells using 4 genes — but stem cells have no identity and would kill you. Sinclair's team found that using only 3 of those genes (OSK, leaving out M) reverses aging 75-80% without erasing cell identity.
